Smirking pharma-bro Martin Shkreli first came to public attention when he hiked the price of a drug used by people with HIV from $13.50/pill to $750/pill.
When Shkreli's financial antics landed him in prison, he packed the board of his pharma company with cronies who maintained his 50% ownership stake in the company. But Shrkeli isn't getting rich while he rots in prison: instead, his company Vyera Pharma (formerly Turing Pharma, soon to be rebranded, again, as Phoenixus, no, really) is spurting uncontrollable gouts of money from every orifice.
That's because the population of patients who take Daraprim -- the drug Shkreli gouged on -- is dwindling, and the remaining patients can't get their insurers to pay $750/pill.
The company’s revenue, which is largely reliant on Daraprim sales, peaked in 2016, reaching more than $78.5 million on the year and helping the company to a profit of $1.3 million. Sales slipped to $67 million in 2017. The company managed a $13.9 million profit thanks to a few one-time benefits and double-digit cuts to expenses and R&D investment.
But Daraprim’s negative sales trends seem to be catching up to Vyera. In the first quarter of 2018, the company booked just $15.7 million in sales. And, for the first time since the price hike, the company’s expenses outpaced its revenue, resulting in a loss of $1.2 million on the quarter.
Three years after steep price hike, Martin Shkreli’s drug company is losing money, documents show [Damian Garde and Adam Feuerstein/Stat]
(via Naked Capitalism)
The employee uprising over Google's secret "Project Dragonfly -- a plan to release a censored, surveilling search engine for use in China -- has reportedly attained its goals: some of the engineers on the covert team Project Dragonfly team have been re-tasked to other projects, and the remainder have been denied access to the critical […]
The fight against surveillance capitalism and mass state surveillance has reached a tipping point, the peak-indifference moment, when new privacy advocates are self-radicalizing as they witness firsthand the undeniable risks of overcollection, over-retention, and secret manipulation of personal data.
In a deeply researched longread, New York Times investigative reporters Walt Bogdanich and Michael Forsythe document in fine detail the role played by the ubiquitous McKinsey and Company in legitimizing, coordinating, and supercharging the world's most notorious human-rights-abusing regimes, from Saudi Arabia to China to Russia.
For the true audio enthusiast, there’s a lot of difference between putting on some songs “for background music” and a true listening experience. For the latter, there’s nothing like a pair of sturdy headphones and the powerful speakers that come with them. And the wireless variety doesn’t get much more powerful than the TREBLAB Z2 […]
Digital or analog, there’s a path of least resistance for any project. Finding that path is what the Agile methodology is all about, which is why proficiency in it is a must for any project management position – and the paycheck that comes with it. And the quickest path to learning Agile? The Agile Project […]
Everybody’s flown a paper airplane. But what if you could fly on a paper airplane? Until we invent shrink-ray technology, the PowerUp X FPV Video Paper Airplane Kit will have to do – but it’s as fun as that sounds and more. The original version of this creative toy added drone tech to the old, […]